The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

Peer Review reports

Original Submission
19 Oct 2018	Submitted	Original manuscript
29 Nov 2018	Reviewed	Reviewer Report - Noboru Hara
10 Dec 2018	Reviewed	Reviewer Report - Tsukasa Igawa
27 Dec 2018	Author responded	Author comments - Naoki Terada
Resubmission - Version 2
27 Dec 2018	Submitted	Manuscript version 2
23 Jan 2019	Reviewed	Reviewer Report - Tsukasa Igawa
29 Jan 2019	Reviewed	Reviewer Report - Noboru Hara
30 Jan 2019	Author responded	Author comments - Naoki Terada
Resubmission - Version 3
30 Jan 2019	Submitted	Manuscript version 3
Publishing
1 Feb 2019	Editorially accepted
15 Feb 2019	Article published	10.1186/s12885-019-5342-9

Back to article page